Pharmacogenetic studies related to cyclophosphamide-based therapy

PintoN.; LudemanS.M.; DolanM.E.

首页> 外文期刊>Pharmacogenomics >Pharmacogenetic studies related to cyclophosphamide-based therapy

【24h】

Pharmacogenetic studies related to cyclophosphamide-based therapy

机译：与基于环磷酰胺的疗法有关的药物遗传学研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Cyclophosphamide is a cornerstone in the treatment of many pediatric and adult malignancies, as well as in the treatment of refractory autoimmune conditions. Genetic factors are thought to play a role in the interindividual variation in both response and toxicities associated with cyclophosphamide-based therapies. This drug focus reviews the most compelling studies conducted on the pharmacogenetics of cyclophosphamide-based therapies. Broader pharmacogenomic studies are needed and may reveal additional factors important in susceptibility to toxicity and/or response to therapy.

机译：环磷酰胺是治疗许多儿科和成人恶性肿瘤以及治疗难治性自身免疫疾病的基石。遗传因素被认为在与环磷酰胺为基础的治疗相关的反应和毒性之间的个体差异中起作用。该药物重点是对基于环磷酰胺的疗法的药物遗传学进行的最引人注目的研究。需要进行更广泛的药物基因组学研究，并且可能揭示出对毒性和/或治疗反应敏感的重要其他因素。

著录项

来源
《Pharmacogenomics》 |2009年第12期|共7页
作者
PintoN.; LudemanS.M.; DolanM.E.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Drug Focus: Pharmacogenetic studies related to cyclophosphamide-based therapy [J] . Navin Pinto, Susan M Ludeman, M Eileen Dolan Pharmacogenomics . 2009,第12期

机译：药物重点：与基于环磷酰胺的疗法有关的药物遗传学研究
2. A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy. [J] . Segawa Y, Aogi K, Inoue Annals of oncology: official journal of the European Society for Medical Oncology . 2009,第11期

机译：帕洛诺司琼II期剂量范围研究在接受中等促呕吐化疗（包括蒽环类和环磷酰胺类化疗）的日本患者中进行。
3. A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy [J] . Y. Segawa1* K. Aogi2 K. Inoue3 M. Sano4 I. Sekine5 Y. Tokuda6 H. Isobe7 T. Ogura8 M. Tsuboi9 S. Atagi10 and for the PALO Japanese Cooperative Study Group Annals of Oncology . 2009,第11期

机译：帕洛诺司琼II期剂量范围研究在接受中度呕吐化疗（包括蒽环类和环磷酰胺类化疗）的日本患者中
4. Pharmacogenetics of inflammatory bowel disease therapy [C] . M. SCHWAB, E. SCHAEFFELER Falk Symposium . 2005

机译：炎症性肠病疗法的药物遗传学
5. Pharmacogenetic studies of membrane transporters relevant to anti-cancer drug therapy. [D] . Badagnani, Ilaria. 2006

机译：与抗癌药物治疗相关的膜转运蛋白的药物遗传学研究。
6. Pharmacogenetic studies related to cyclophosphamide-based therapy [O] . Navin Pinto, Susan M Ludeman, M Eileen Dolan -1

机译：与基于环磷酰胺的治疗有关的药物遗传学研究
7. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy. [O] . Kuan-Yeh Lee, Shu-Wen Lin, Hsin-Yun Sun, 2014

机译：HIV感染华人的治疗药物监测和药物遗传学研究接受含有efavirenz的抗逆转录病毒治疗，有或没有基于利福平的抗结核治疗。

Pharmacogenetic studies related to cyclophosphamide-based therapy

摘要

著录项

相似文献

相关主题

期刊订阅